MannKind (MannKind) Risk Assessment

View and export this data going back to 2004. Start your Free Trial

What is MannKind Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of MannKind is: High Risk: High uncertainty.

Competitive Comparison of MannKind's Risk Assessment

For the Biotechnology subindustry, MannKind's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MannKind's Risk Assessment Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MannKind's Risk Assessment distribution charts can be found below:

* The bar in red indicates where MannKind's Risk Assessment falls into.

MannKind (NAS:MNKD) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

MannKind Risk Assessment Related Terms

Thank you for viewing the detailed overview of MannKind's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

MannKind (MannKind) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MannKind Corp (NAS:MNKD) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

NNFN:Germany

Address

1 Casper Street, Danbury, CT, USA, 06810

Website

https://www.mannkindcorp.com

MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.

Executives

Michael Castagna	officer: Chief Commercial Officer	25134 RYE CANYON LOOP, SUITE 300, VALENCIA CA 91355
David Thomson	officer: VP & Assoc General Counsel	28903 NORTH AVENUE PAINE, VALENCIA CA 91355
Steven B. Binder	officer: Chief Financial Officer	30930 RUSSELL RANCH ROAD, SUITE 300, WESTLAKE VILLAGE CA 91362
Burkhard Blank	officer: EVP Chief Medical Officer	C/O ACORDA THERAPEUTICS, 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Lauren M Sabella	officer: EVP Chief Operating Officer	C/O ACORDA THERAPEUTICS, 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Sanjay R Singh	officer: EVP Technical Operations	1 CASPER STREET, DANBURY CT 06810
Alejandro Galindo	officer: Chief Commercial Officer	30930 RUSSELL RANCH RD, STE 300, WESTLAKE VILLAGE CA 91362
Stuart A Tross	officer: Corp VP, Chief People Officer	ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Anthony C Hooper	director	AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Jennifer Grancio	director	30930 RUSSELL RANCH ROAD SUITE 300, WESTLAKE VILLAGE CA 91362
Christine Mundkur	director
Sabrina Kay	director	30930 RUSSELL RANCH ROAD, SUITE 300, WESTLAKE VILLAGE CA 91362
David M Kendall	officer: Chief Medical Officer	30930 RUSSELL RANCH ROAD, WESTLAKE VILLAGE CA 91362
Patrick Mccauley	officer: Chief Commercial Officer	30930 RUSSELL RANCH ROAD, SUITE 300, WESTLAKE VILLAGE CA 91362
Barton Courtney	officer: Chief Compliance Officer	30930 RUSSELL RANCH ROAD, WESTLAKE VILLAGE CA 91362